4//SEC Filing
Rizvi Naiyer 4
Accession 0000899243-18-017719
CIK 0001693664other
Filed
Jun 21, 8:00 PM ET
Accepted
Jun 22, 5:14 PM ET
Size
9.3 KB
Accession
0000899243-18-017719
Insider Transaction Report
Form 4
Rizvi Naiyer
Director
Transactions
- Disposition to Issuer
Stock Option (right to buy)
2018-06-22$10.03/sh−18,000$180,540→ 0 totalExercise: $39.97Exp: 2028-03-25→ Common Stock (18,000 underlying) - Disposition to Issuer
Stock Option (right to buy)
2018-06-22$43.27/sh−19,146$828,365→ 0 totalExercise: $6.73Exp: 2027-07-26→ Common Stock (19,146 underlying)
Footnotes (4)
- [F1]Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated May 9, 2018, by and among the Issuer, Eli Lilly and Company ("Parent") and Bluegill Acquisition Corporation ("Merger Sub"), a wholly-owned subsidiary of Parent, Merger Sub made a cash tender offer (the "Offer") to purchase each outstanding share of the Issuer's common stock for $50.00 per share (the "Offer Price"), net to the seller in cash, without interest and less any applicable tax withholding. These shares were tendered into the Offer and, after the expiration of the Offer at one minute after 11:59 pm Eastern Time on June 21, 2018, Merger Sub accepted all of the tendered shares and the holder was entitled to receive the Offer Price per share.
- [F2]Pursuant to the Merger Agreement, each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $50.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option.
- [F3]This option, which provided for vesting in thirty-six equal monthly installments following March 31, 2018, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above.
- [F4]This option, which provided for vesting in forty-eight equal monthly installments following June 20, 2017, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above.
Documents
Issuer
ARMO BioSciences, Inc.
CIK 0001693664
Entity typeother
Related Parties
1- filerCIK 0001728740
Filing Metadata
- Form type
- 4
- Filed
- Jun 21, 8:00 PM ET
- Accepted
- Jun 22, 5:14 PM ET
- Size
- 9.3 KB